A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation - Join Clinical Trial NCTNCT06789913
How to Join This Clinical Trial - NCTNCT06789913
Learn how to participate in this PHASE2 trial studying an investigational therapy for PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations, PIK3CA Mutation, CLOVES Syndrome, Klippel Trenaunay Syndrome, Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP). This study is currently enrolling participants.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations, PIK3CA Mutation, CLOVES Syndrome, Klippel Trenaunay Syndrome, Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP). Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations, PIK3CA Mutation, CLOVES Syndrome, Klippel Trenaunay Syndrome, Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)
- Treatment Being Tested
- Investigational treatment
- Study Phase
- PHASE2 - Safety and effectiveness study
- Enrollment Status
- Currently enrolling participants
- Study Identifier
- NCTNCT06789913 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at 7 locations. Find a study site near you:
Clinical Research Site
Little Rock, Arkansas 72202 - United States
Status: RECRUITING
Clinical Research Site
San Francisco, California 94158 - United States
Status: RECRUITING
Clinical Research Site
Rochester, Minnesota 55905 - United States
Status: RECRUITING
Clinical Research Site
St. Louis, Missouri 63110 - United States
Status: RECRUITING
Clinical Research Site
Cincinnati, Ohio 45229 - United States
Status: RECRUITING
Clinical Research Site
Cleveland, Ohio 44195 - United States
Status: RECRUITING
Clinical Research Site
Houston, Texas 77030 - United States
Status: RECRUITING
How to Enroll in This Study
To learn more about participating in this PHASE2 clinical trial for PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations, Vascular Malformations, PIK3CA Mutation, CLOVES Syndrome, Klippel Trenaunay Syndrome, Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP):
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai Study Finder
Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:
- Discover clinical trials before competitors
- Access exclusive contact information
- Track sponsor pipelines and opportunities
- Connect with decision makers directly
- Win more business partnerships